The prevalence of the mutation in codon 249 of the P53 Gene in Patients with Hepatocellular Carcinoma (HCC) in Turkey

被引：8

作者：

Özdemir F.T. ^{[1
]}

Tiftikci A. ^{[2
]}

Sancak S. ^{[3
]}

Eren F. ^{[1
]}

Tahan V. ^{[1
]}

Akın H. ^{[1
]}

Gündüz F. ^{[1
]}

Kedrah A.E. ^{[1
]}

Üstündağ Y. ^{[4
]}

Avşar E. ^{[1
]}

Tözün N. ^{[2
]}

Özdoğan O. ^{[1
]}

机构：

[1] Institute of Gastroenterology, Marmara University, Istanbul

[2] School of Medicine, Department of Gastroenterology, Acibadem University, Istanbul

[3] School of Medicine, Department of Endocrinology, Marmara University, Istanbul

[4] School of Medicine, Department of Gastroenterology, Zonguldak Karaelmas University, Zonguldak

来源：

Journal of Gastrointestinal Cancer | 2010年 / 41卷 / 3期

关键词：

Aflatoxin; Chronic hepatitis B; Cirrhosis; Hepatocellular cancer; P53; codon; 249;

D O I：

10.1007/s12029-010-9140-5

中图分类号：

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is one of the most common cancers in the worldwide. Aflotoxins, products of Aspergillus Flavus found in the high humidity environments induce HCC in humans by causing mutations in oncogenes such as codon 249 mutation of p53 in hepatocytes. In turkey, aflatoxins are found to be increased in some foods in certain areas, such as Istanbul which have high humidity. In present study we aimed to look for the prevalence of codon 249 mutation of p53 in patients with HCC, cirrhosis and chronic hepatitis B (CHB). Methods DNA was extracted from plasma and mutation was detected by PCR-RFLP method. Results the codon 249 mutation of p53 is found one out of 50 HCC (2%) patients. In conclusion, although codon 249 mutation of p53 gene has been found very rare but it exists showing the effect of aflatoxins in HCC patients in Turkey. © Springer Science+Business Media, LLC 2010.

引用

页码：185 / 189

页数：4

共 36 条

[1]

Parkin D.M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002, CA Cancer J Clin., 55, 29, pp. 74-108, (2005)

[2]

Bosch F.X., Ribes J., Diaz M., Cleries R., Primary liver cancer: Worldwide incidence and trends, Gastroenterology, 127, 5 SUPPL. 1, pp. 5-16, (2004)

[3]

Llovet J.M., Burroughs A., Bruix J., Hepatocellular carcinoma, Lancet, 362, 9399, pp. 1907-1917, (2003)

[4]

Ozer B., Serin E., Yilmaz U., Et al., Clinicopathologic features and risk factors for hepatocellular carcinoma: Results from a single center in southern Turkey, Turk J Gastroenterol, 14, 2, pp. 85-90, (2003)

[5]

Stern M.C., Umbach D.M., Yu M.C., Et al., Hepatitis B, aflatoxin B1 and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies, Cancer Epidemiol Biomark Prev, 10, pp. 617-625, (2001)

[6]

Yan R.Q., Su J.J., Huang D.R., Et al., Human hepatitis B virus and hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflotoxin B1, Cancer Res Clin Oncol, 122, pp. 289-295, (1996)

[7]

Kirk G.D., Camus-Randon A.M., Mendy M., Et al., Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia, J Natl Cancer Inst, 92, 2, pp. 148-153, (2000)

[8]

Dong-Dong L., Xi-Ran Z., Plasma 249Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area, J Cell Mol Med, 7, 1, pp. 89-92, (2003)

[9]

Jackson P.E., Kuang S.Y., Wang J.B., Et al., Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients, Carcinogenesis, 24, 10, pp. 1657-1663, (2003)

[10]

Szymanska K., Lesi O.A., Kirk G.D., Et al., Ser249 TP53 mutation in tumor and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa, Int J Cancer, 110, pp. 374-379, (2004)

← 1 2 3 4 →